Cargando…

Should dialysis be offered in all cases of metformin-associated lactic acidosis?

Metformin is commonly used in diabetes mellitus type 2, with lactic acidosis being a rare but potentially fatal complication of this therapy. The management of metformin-associated lactic acidosis (MALA) is controversial. Treatment may include supportive care, activated charcoal, bicarbonate infusio...

Descripción completa

Detalles Bibliográficos
Autor principal: Finkle, S Neil
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2688106/
https://www.ncbi.nlm.nih.gov/pubmed/19216723
http://dx.doi.org/10.1186/cc7161
_version_ 1782167651271835648
author Finkle, S Neil
author_facet Finkle, S Neil
author_sort Finkle, S Neil
collection PubMed
description Metformin is commonly used in diabetes mellitus type 2, with lactic acidosis being a rare but potentially fatal complication of this therapy. The management of metformin-associated lactic acidosis (MALA) is controversial. Treatment may include supportive care, activated charcoal, bicarbonate infusion, hemodialysis, or continuous venovenous hemofiltration. In the previous issue of Critical Care, Peters and colleagues systematically evaluated outcomes in MALA patients admitted to their intensive care unit. The mortality rate of patients who received dialysis was similar to that of patients who were not dialyzed. However, it was the more acutely and chronically ill patients who actually received dialysis. This suggests that hemodialysis was beneficial in preventing a higher mortality rate in those who required renal replacement therapy.
format Text
id pubmed-2688106
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26881062010-01-09 Should dialysis be offered in all cases of metformin-associated lactic acidosis? Finkle, S Neil Crit Care Commentary Metformin is commonly used in diabetes mellitus type 2, with lactic acidosis being a rare but potentially fatal complication of this therapy. The management of metformin-associated lactic acidosis (MALA) is controversial. Treatment may include supportive care, activated charcoal, bicarbonate infusion, hemodialysis, or continuous venovenous hemofiltration. In the previous issue of Critical Care, Peters and colleagues systematically evaluated outcomes in MALA patients admitted to their intensive care unit. The mortality rate of patients who received dialysis was similar to that of patients who were not dialyzed. However, it was the more acutely and chronically ill patients who actually received dialysis. This suggests that hemodialysis was beneficial in preventing a higher mortality rate in those who required renal replacement therapy. BioMed Central 2009 2009-01-09 /pmc/articles/PMC2688106/ /pubmed/19216723 http://dx.doi.org/10.1186/cc7161 Text en Copyright © 2009 BioMed Central Ltd
spellingShingle Commentary
Finkle, S Neil
Should dialysis be offered in all cases of metformin-associated lactic acidosis?
title Should dialysis be offered in all cases of metformin-associated lactic acidosis?
title_full Should dialysis be offered in all cases of metformin-associated lactic acidosis?
title_fullStr Should dialysis be offered in all cases of metformin-associated lactic acidosis?
title_full_unstemmed Should dialysis be offered in all cases of metformin-associated lactic acidosis?
title_short Should dialysis be offered in all cases of metformin-associated lactic acidosis?
title_sort should dialysis be offered in all cases of metformin-associated lactic acidosis?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2688106/
https://www.ncbi.nlm.nih.gov/pubmed/19216723
http://dx.doi.org/10.1186/cc7161
work_keys_str_mv AT finklesneil shoulddialysisbeofferedinallcasesofmetforminassociatedlacticacidosis